These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 39110275)

  • 1. Monitoring of estradiol levels in premenopausal women receiving adjuvant abemaciclib and ovarian function suppression.
    Kessler AJ; Patel R; Gallagher EJ; Sheng T; Mendu DR; Tiersten A; Klein P; Bhardwaj AS; Goel A; Sparano JA; Shao T; Fasano J
    Breast Cancer Res Treat; 2024 Oct; 207(3):529-532. PubMed ID: 39110275
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discrepancies in estradiol levels in a premenopausal woman receiving abemaciclib despite ovarian function suppression and bilateral salpingo-oophorectomy.
    Kessler AJ; Patel R; Gallagher EJ; Shao T; Fasano J
    Curr Probl Cancer Case Rep; 2023 Mar; 9():. PubMed ID: 37124155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ovarian suppression for adjuvant treatment of hormone receptor-positive early breast cancer.
    Bui KT; Willson ML; Goel S; Beith J; Goodwin A
    Cochrane Database Syst Rev; 2020 Mar; 3(3):CD013538. PubMed ID: 32141074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of Adjuvant Ovarian Function Suppression in Premenopausal Women With Early Breast Cancer: A Multicenter Cohort Study.
    Ferreira AR; Ribeiro J; Miranda A; Mayer A; Passos-Coelho JL; Brito M; Fernandes J; Gouveia J; Costa L; Vaz-Luis I
    Clin Breast Cancer; 2019 Oct; 19(5):e654-e667. PubMed ID: 31327728
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Abemaciclib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in premenopausal women: subgroup analysis from the MONARCH 2 trial.
    Neven P; Rugo HS; Tolaney SM; Iwata H; Toi M; Goetz MP; Kaufman PA; Lu Y; Haddad N; Hurt KC; Sledge GW
    Breast Cancer Res; 2021 Aug; 23(1):87. PubMed ID: 34425869
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ovarian Function Suppression in Premenopausal Women With Concurrent Endocrine Therapy Use.
    Fleege NMG; Li Y; Kidwell KM; Henry NL
    Clin Breast Cancer; 2023 Jun; 23(4):454-460. PubMed ID: 37076363
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Navigating the Challenges of Endocrine Treatments in Premenopausal Women with ER-Positive Early Breast Cancer.
    Colleoni M; Munzone E
    Drugs; 2015 Aug; 75(12):1311-21. PubMed ID: 26177891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant endocrine therapy for premenopausal women with hormone-responsive breast cancer.
    Mathew A; Davidson NE
    Breast; 2015 Nov; 24 Suppl 2():S120-5. PubMed ID: 26255743
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant treatment of premenopausal women with endocrine-responsive early breast cancer: design of the TEXT and SOFT trials.
    Regan MM; Pagani O; Fleming GF; Walley BA; Price KN; Rabaglio M; Maibach R; Ruepp B; Coates AS; Goldhirsch A; Colleoni M; Gelber RD; Francis PA; ;
    Breast; 2013 Dec; 22(6):1094-100. PubMed ID: 24095609
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The aromatase inhibitors (plus ovarian function suppression) in premenopausal breast cancer patients: ready for prime time?
    Montagna E; Cancello G; Colleoni M
    Cancer Treat Rev; 2013 Dec; 39(8):886-90. PubMed ID: 23725877
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant endocrine therapy choices in premenopausal patients with hormone receptor-positive early breast cancer: Insights from the prospective GIM23-POSTER study.
    Arecco L; Latocca MM; Blondeaux E; Riccardi F; Mocerino C; Guarneri V; Mioranza E; Bisagni G; Gasparini E; Puglisi F; Membrino A; Ferro A; Adamo V; Giovanardi F; Tamberi S; Donati S; Landucci E; Biganzoli L; Piccinini S; Pastorino S; de Azambuja E; Poggio F; Lambertini M; Del Mastro L
    Breast; 2024 Oct; 77():103769. PubMed ID: 39043079
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of gonadotropin-releasing hormone agonists for ovarian function suppression in premenopausal patients with hormone receptor-positive breast cancer: a retrospective single-center real-world study.
    Chen Y; Zhang R; Yan Y; Li H; Song G
    Breast Cancer Res Treat; 2024 Aug; 206(3):543-550. PubMed ID: 38709374
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Myocardial Function in Premenopausal Women Treated With Ovarian Function Suppression and an Aromatase Inhibitor.
    Jordan JH; D'Agostino RB; Ansley K; Douglas E; Melin S; Sorscher S; Vasu S; Park S; Kotak A; Romitti PA; O'Connell NS; Hundley WG; Thomas A
    JNCI Cancer Spectr; 2021 Aug; 5(4):. PubMed ID: 34476341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact on disease-free survival of the duration of ovarian function suppression, as postoperative adjuvant therapy, in premenopausal women with hormone receptor-positive breast cancer: a retrospective single-institution study.
    Ozaki Y; Tanabe Y; Tamura N; Ogura T; Kondoh C; Miura Y; Yoshimura K; Kawabata H; Takano T
    Breast Cancer; 2018 May; 25(3):343-349. PubMed ID: 29357022
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Luteininzing hormone releasing hormones analogs in combination with tamoxifen for the adjuvant treatment of premenopausal women with hormone receptor positive breast cancer.
    Conte B; Poggio F; Del Mastro L
    Expert Opin Pharmacother; 2017 Sep; 18(13):1357-1362. PubMed ID: 28764603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treating HR+/HER2- breast cancer in premenopausal Asian women: Asian Breast Cancer Cooperative Group 2019 Consensus and position on ovarian suppression.
    Yeo W; Ueno T; Lin CH; Liu Q; Lee KH; Leung R; Naito Y; Park YH; Im SA; Li H; Yap YS; Lu YS;
    Breast Cancer Res Treat; 2019 Oct; 177(3):549-559. PubMed ID: 31270763
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Measurable Serum Estradiol and Estrone in Women 36-56 Years During Adjuvant Treatment With Aromatase Inhibitors for a Hormone Receptor-Positive Breast Cancer. Case Studies and Cross-sectional Study Using an Ultra-sensitive LC-MS/MS-Method.
    Van Houdt M; Han SN; Pauwels S; Billen J; Neven P
    Clin Breast Cancer; 2023 Jan; 23(1):84-90. PubMed ID: 36376236
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world treatment patterns of adjuvant endocrine therapy and ovarian suppression in premenopausal HR+/HER2+ breast cancer.
    Sukumar JS; Sardesai S; Ni A; Williams N; Johnson K; Quiroga D; Ramaswamy B; Wesolowski R; Cherian M; Stover DG; Gatti-Mays M; Pariser A; Sudheendra P; George MA; Lustberg M
    Cancer Med; 2024 Jun; 13(12):e7317. PubMed ID: 38895891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant endocrine therapy for premenopausal women: risk stratification, type and duration.
    Francis PA
    Breast; 2019 Nov; 48 Suppl 1():S85-S88. PubMed ID: 31839169
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Factors related to adjuvant ovarian function suppression in premenopausal breast cancer patients].
    Liang Y; Chen XS; Wu JY; Huang O; Zong Y; Nie LJ; Fang Q; He JR; Zhu L; Chen WG; Li YF; Shen KW
    Zhonghua Zhong Liu Za Zhi; 2016 May; 38(5):357-62. PubMed ID: 27188608
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.